The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.
Redenlab was the speech biomarker provider on the trial with Retrotope.
Click here to find out more.
